SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
Key Highlights
- ➤SOTERIA and Tempus (TEM) collaborate on precision oncology for military populations
- ➤Tempus provides comprehensive genomic profiling and AI-enabled diagnostic support
- ➤Cancer Hunt initiative targets active-duty and veteran cancer treatment navigation
- ➤Collaboration integrates molecular profiling to identify therapies and clinical trials
Expert Statements
Julia Civardi, Founder and CEO of SOTERIA
“Our mission is to ensure that patients have access to the tools and technology that can inform the most effective treatment path for them.”
Julia Civardi, Founder and CEO of SOTERIA
“Partnering with Tempus enables us to bring state-of-the-art genomic sequencing and AI analytics to our active service members and veterans, turning complex molecular data into clear, actionable treatment options for patients and care teams.”
Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus
“Collaborating with SOTERIA allows us to put cutting-edge genomic insights directly into the hands of clinicians and their patients when every decision matters most.”
Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus
“We are proud to support SOTERIA's mission and help advance precision oncology for our nation's service members and veterans.”
CAPT Rob Newson, SEAL, USN (RET), PhD, Chief Community Officer at SOTERIA
“As a member of the Special Operations community, I've seen the immense toll these cancers take.”
CAPT Rob Newson, SEAL, USN (RET), PhD, Chief Community Officer at SOTERIA
“This initiative reflects the best of what's possible when technological innovation and service come together to support our military families.”
SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer PR Newswire
SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation , a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt(™) initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities for active service members and veterans.
Get started
Create a free account to read the full story.